Medifast (MED) Expected to Announce Quarterly Earnings on Monday

Key Points

• Medifast is expected to report its Q2 2025 quarterly earnings on Monday, August 4th, with analysts predicting a loss of ($0.22) per share and revenue of $96.10 million.
• The company last reported earnings in April, missing consensus estimates, and had a revenue of $115.73 million for that quarter, while analysts project earnings of $1 per share for the current fiscal year.
• Hedge funds have been active with their positions in Medifast, with institutions owning 95.51% of the stock; Strs Ohio and Amundi have recently increased their stakes.

Medifast (NYSE:MED - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Monday, August 4th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $96.10 million for the quarter.

Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The specialty retailer reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The business had revenue of $115.73 million during the quarter, compared to analyst estimates of $114.85 million. Medifast had a positive return on equity of 6.63% and a negative net margin of 1.29%. On average, analysts expect Medifast to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Medifast Trading Down 1.5%

Shares of NYSE:MED opened at $14.89 on Monday. The firm has a 50 day moving average of $13.88 and a 200-day moving average of $14.01. The stock has a market capitalization of $163.62 million, a PE ratio of -22.90 and a beta of 0.86. Medifast has a 12 month low of $11.57 and a 12 month high of $22.66.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Medifast from a "hold" rating to a "buy" rating in a research report on Thursday, May 1st.

Hedge Funds Weigh In On Medifast

Hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio acquired a new position in shares of Medifast in the 1st quarter valued at approximately $78,000. Amundi raised its position in shares of Medifast by 43.5% in the 1st quarter. Amundi now owns 30,439 shares of the specialty retailer's stock valued at $398,000 after buying an additional 9,224 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Medifast by 14.5% in the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer's stock valued at $2,693,000 after buying an additional 25,366 shares in the last quarter. 95.51% of the stock is currently owned by institutional investors and hedge funds.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.